Matches 1 - 50 out of 213 1 2 3 4 5 >


Match Document Document Title
US20120083449 TREATMENT FOR ANXIETY  
The invention provides methods of treating or effecting prophylaxis of a patient having or at risk of developing symptoms of anxiety in which an effective regime of an agent that inhibits specific...
US20110256130 METHODS OF TREATING INFLAMMATORY DISORDERS  
Disclosed herein, in certain embodiments, are methods and compositions for treating inflammatory disorders. In some embodiments, the methods comprise co-administering synergistic combinations of...
US20110224144 COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING MENTAL DISORDERS  
The present invention provides methods for diagnosing mental disorders (e.g., psychotic disorders such as schizophrenia). The invention also provides methods of identifying modulators of such...
US20120148583 CYTOKINE ANTAGONISTS FOR NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS  
A method for delivering a biologic pharmaceutical, comprising: administering an effective amount of a biologic pharmaceutical to a patient in need thereof by perispinal injection, without direct...
US20110269688 Genetic Alterations Associated with Schizophrenia and Methods of Use Thereof for the Diagnosis and Treatment of the Same  
Compositions and methods for the detection and treatment of schizophrenia are provided.
US20110212895 Treatment of Cognitive and Learning Impairment  
Constitutive activators of Rho GTPases are useful in treating learning an cognitive disorders.
US20150023949 COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDER  
Methods for treatment and diagnosis of pervasive developmental disorders in humans are described.
US20110257101 CATECHOLAMINE REGULATED PROTEIN  
A novel mammalian catecholamine-regulated protein called CRP40 is identified. This protein, and nucleic acid encoding same, is useful in methods of diagnosing and treating hypodopaminergic...
US20110201542 Myeloid Protein Activation of Anti-Inflammatory and Anti-Hypoxic Pathway  
Provided are methods to enhance healing of wounds and tissue, especially during or pursuant to psychological and/or physical stress and to protect tissue from deleterious effects associated with...
US20140073562 NASAL DELIVERY  
A nasal delivery device for and method of delivering a substance, preferably comprising oxytocin, non-peptide agonists thereof and antagonists thereof, preferably as one of a liquid, as a...
US20110262386 METHODS OF TREATING INFLAMMATION  
Disclosed herein, in certain embodiments, is a method for treating an MIF-mediated disorder. In some embodiments, the method comprises administering an active agent that inhibits (i) MIF binding...
US20110189161 NUTRIGENOMICS METHODS AND COMPOSITIONS  
The present invention provides a proprietary compositions and systems to modulate genetic and metabolomic contributing factors affecting disease diagnosis, stratification, and prognosis, as well...
US20110294727 COMPOSITIONS OF NUTRITION SUPPLEMENTATION FOR NUTRITIONAL DEFICIENCIES AND METHOD OF USE THEREFORE  
A nutritional supplement composition for treating nutritional deficiencies caused by a medical condition in subjects is disclosed. The present application further discloses a method of using a...
US20120321609 METHOD OF TREATING PSYCHOLOGICAL DISORDERS  
A method of desensitizing 5-HT2R signaling in the mammal is provided. The method comprises one or more of: 1) inhibiting CRFR1 activation of 5-HT2AR signaling by preventing trafficking of...
US20120196809 USE OF ICAM-1 FOR PREVENTION OR TREATMENT OF NEUROLOGICAL DISEASES  
The present invention relates to a pharmaceutical composition for the prevention or treatment of neurological disorders, comprising an ICAM-1 (intercellular adhesion molecule-1) protein, or a...
US20140323408 METHOD OF INHIBITING DOPAMINERGIC CELL DEATH  
Soluble Neuregulin-1 isoforms representing Posttranslational Neuregulin-1 modifications for reducing dopaminergic cell death.
US20110104181 MODULATION OF SYNAPTOGENESIS  
The present invention describes methods and compositions for modulating synaptogenesis and axon and/or dendritic growth. The methods include the use of agents that modulate a thrombospondin and/or...
US20110288027 TARGETS, METHODS, AND REAGENTS FOR DIAGNOSIS AND TREATMENT OF SCHIZOPHRENIA  
The present invention provides targets, methods, and reagents for the diagnosis and treatment of schizophrenia and related conditions. The invention provides methods for the diagnosis of...
US20110172158 TARGETS, METHODS, AND REAGENTS FOR DIAGNOSIS AND TREATMENT OF SCHIZOPHRENIA  
The present invention provides targets, methods, and reagents for the diagnosis and treatment of schizophrenia and related conditions. The invention provides methods for the diagnosis of...
US20110294739 USE OF THE ENGRAILED HOMEODOMAIN PROTEIN AS ANXIOLYTIC  
The present invention relates to the use of an Engrailed transcription factor for producing a medicament for anxiolytic purposes.
US20060135422 Use of angiotensin receptor blockers (ARBs) to treat diseases associated with excess ACE  
Disclosed are methods of treating neuropsychiatric diseases, neuromuscular diseases, viral infections, neurodegenerative diseases and ricin poisoning using angiotensin II receptor blockers.
US20120134991 COMPOSITIONS AND METHODS FOR MODULATING D1-D2 DOPAMINE RECEPTOR INTERACTION AND FUNCTION  
The present invention provides for prevention and/or treatment of neurological or neuropsychiatric disorders involving abnormal D1-D2 dopamine receptor coupling and/or activation. Methods and...
US20150140046 COMPOUNDS WHICH INHIBIT NEURONAL EXOCYTOSIS  
Compounds of general formula (I): R1-Wn-Xm-AA1-AA2-AA3-AA4-AA5-AA6-AA7-AA8-AA9-Yp-Zq-R2 (I) their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts,...
US20130345122 COMPOSITIONS AND METHODS FOR MODULATING DOPAMINE NEUROTRANSMISSION  
The present invention provides for diagnosis or treatment of neurological or neuropsychiatric disorders involving abnormal dopamine neurotransmission. Methods and agents are provided for...
US20130035293 COMPOSITIONS AND METHODS FOR MODULATING DOPAMINE NEUROTRANSMISSION  
The present invention provides for diagnosis or treatment of neurological or neuropsychiatric disorders involving abnormal dopamine neurotransmission. Methods and agents are provided for...
US20110183909 Treatment of Mood and Anxiety Disorders  
The invention relates to a selective inhibitor of Elk-1 or MSK-1 activation for use in the prevention and/or treatment of mood and anxiety disorders.
US20150004165 SECRETED PROTEINS  
The invention provides human secreted proteins (SECP) and polynucleotides which identify and encode SECP. The invention also provides expression vectors, host cells, antibodies, agonists, and...
US20120021991 USE OF A BOTULINUM NEUROTOXIN TO ALLEVIATE VARIOUS DISORDERS  
Methods for treating obsessions and compulsions by local administration of a Clostridial toxin. The obsessions or compulsions can be eye poking, body rocking, finger biting, counting, checking and...
US20110076347 Molecules Interfering with Binding of Calbindin to Inositol Monophosphatase for the Treatment of Mood Disorders  
This invention provides derivatives of dodecapeptide ISSIKEKYPSHS which interfere with binding of calbindin to inositol monophosphatase, and their use in treating mood disorders.
US20120129780 LACTOFERRIN AND BRAIN HEALTH AND PROTECTION IN ADULTS  
The present invention relates generally to the field of brain health, brain protection, maintenance of cognitive function, prevention of cognitive decline and cognitive disorders. Neuronal cells...
US20120135935 GPR54 AGONISTS OR ANTAGONISTS FOR TREATMENT OF DISEASES PRESENTING BEHAVIORAL ABNORMALITIES  
Use of a GPR54 agonist or antagonist for the treatment of a disease or disorder presenting behavioral abnormalities associated with impairment of sensory gating function, and/or for treatment of...
US20110288028 AMYLIN AND AMYLIN AGONISTS FOR TREATING PSYCHIATRIC DISEASES AND DISORDERS  
Methods and compositions for treating psychiatric diseases and disorders are disclosed. The methods provided generally involve the administration of an amylin or an amylin agonist to a subject in...
US20110053843 E-SELECTIN COMPOSITIONS AND USE THEREOF FOR INDUCING E-SELECTIN TOLERANCE  
The invention relates to compositions and methods for treating or preventing vascular dementia in a mammal comprising mucosal administration of an amount of E-selectin polypeptide sufficient to...
US20110311521 Novel therapy for anxiety  
The present invention relates to a method of modulating, treating or effecting prophylaxis of a subject having anxiety or at risk of developing symptoms of anxiety, said method being characterized...
US20140107037 METHODS OF TREATING ALZHEIMER'S DISEASE, HUNTINGTON'S DISEASE, AUTISM, OR OTHER DISORDERS  
The disclosure relates, at least in part, to methods of treating autism in a patient in need thereof by administering an effective amount of a disclosed compound, e.g., a NMDA receptor glycine...
US20150245597 HETEROZYGOUS MOUSE WITH AN INACTIVATED BRD1 ALLELE AND USES IN PSYCHIATRY  
The present invention encompasses genetically modified non-human mammals comprising a genetic modification that inhibits and/or reduces BRD1 activity in one or more tissue or cell, methods of...
US20140294851 CLEAVABLE DRUG CONJUGATES, COMPOSITIONS THEREOF AND METHODS OF USE  
Base-labile crosslinkers, base-labile conjugates comprising such crosslinkers, methods of their synthesis and use are disclosed.
US20120046232 COMPOSITIONS AND METHODS FOR REDUCING RELAPSE OF ADDICTIVE BEHAVIOR  
Disclosed are methods and compositions comprising mGluR modulators and procysteine drugs. The methods and compositions can be used to treat subjects with prior addiction in order to reduce drug...
US20150224164 TREATMENT OF AUTISM SPECTRUM DISORDERS USING GLYCYL-L-2-METHYLPROLYL-L-GLUMATIC ACID  
This invention provides compounds, compositions and methods for treating Autism Spectrum Disorders (ASD) using glycyl-2-methylprolyl-glutamic acid (G-2-MePE) and analogs thereof. Autism Spectrum...
US20150197543 Treatment of Autism Spectrum Disorders Using Glycyl-L-2-Methylprolyl-L-Glutamic Acid  
This invention provides compounds, compositions and methods for treating Autism Spectrum Disorders (ASD) using glycyl-2-methylprolyl-glutamic acid (G-2-MePE) and analogs thereof. Autism Spectrum...
US20140147491 TREATMENT OF AUTISM SPECTRUM DISORDERS USING GLYCYL-L-2-METHYLPROLYL-L-GLUTAMIC ACID  
This invention provides compounds, compositions and methods for treating Autism Spectrum Disorders (ASD) using glycyl-2-methylprolyl-glutamic acid (G-2-MePE) and analogs thereof. Autism Spectrum...
US20110105389 Macrocyclic Ghrelin Receptor Antagonists and Inverse Agonists and Methods of Using the Same  
The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (GRLN, growth hormone...
US20100291196 METHOD OF TREATMENT OF AUTISM SPECTRUM DISORDER WITH LIPOSOMAL REDUCED GLUTATHIONE  
The invention proposes the use of reduced glutathione encapsulated in a liposome (liposomal reduced glutathione) for the oral administration of a therapeutically effective amount to improve...
US20050119162 Novel analgesics  
The object of this invention is to provide a novel pharmaceutical composition for getting rid of pains and anxiety in patients. This invention relates to a pharmaceutical composition containing...
US20120040886 Analogues of Neuropeptide Y Having Proline Substitution At Position 34  
The present invention relates to novel analogues of neuropeptide Y, pharmaceutical compositions containing the same, pharmaceutical formulations containing the same, and method of treating...
US20150219674 AUTISM-ASSOCIATED BIOMARKERS AND USES THEREOF  
The invention discloses biomarkers for human autism. The invention provides methods for treating, preventing, and diagnosing human autism and autism-related disorders.
US20050176650 Stable parenteral formulation of levomepromazine and a method for stabilizing said formulation  
The present invention relates to stabilized formulations for parenteral administration comprising a therapeutically effective amount of levomepromazine or a pharmaceutically acceptable salt...
US20070196355 Method to treat atherosclerosis  
A theory has been presented that provides a simplified explanation of a cohesive mechanism of embryological development, hemostasis, coagulation, wound repair and tissue maintenance that operates...
US20120295852 METHODS OF TREATING DEPRESSION AND OTHER RELATED DISEASES  
The invention relates to methods for treating depression, anxiety, and other related diseases by administering a peptide NMDAR partial agonist.
US20050014698 Compositions for improved oxidative status in companion animals  
A food composition that is useful for increasing antioxidant levels in the body is provided having increased levels of sulfur-containing amino acids, such as methionine, cysteine, or mixtures...

Matches 1 - 50 out of 213 1 2 3 4 5 >